Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule Administration

Exclusion Criteria

• •1. History of complicated/obstructive diverticular disease
• •2. History of intestinal or colonic obstruction, or suspected intestinal obstruction.
• •3. History of significant gastrointestinal disorder, including any form of inflammatory bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has been treated and is in remission)
• •4. History of gastroparesis
• •5. Use of any of the following medications:
• •* Medications that may affect intestinal motility, prokinetics, anti-depressants, anti-Parkinsonian medications, opiates, opioids, calcium-channel blockers, aluminum/magnesium hydroxide
• •* With the exception of antidepressants, thyroid or hormonal replacement therapy, when the subject has been on a stable dose for at least 3 months prior to enrollment.
• •6. Clinical evidence of significant respiratory, cardiovascular, renal, hepatic, biliary, endocrine, psychiatric or neurologic disease.
• •7. Presence of cardiac pacemaker or gastric electrical stimulator.
• •8. History of, or current eating disorders, such as anorexia, bulimia, or compulsory overeating.
• •9. Diagnosis of mega-rectum or colon, congenital anorectal malformation, clinically significant rectocele, history of intestinal resection (with an exception for appendectomy, cholecystectomy and inguinal hernia repair), history of bariatric surgery or evidence of any structural abnormality of the gastrointestinal tract that might affect transit
• •10. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal stricture or achalasia
• •11. Chronic use of non-steroidal anti-inflammatory drugs: chronic use is defined as taking full dose non-steroidal anti-inflammatory drugs more than three times a week for at least six months. Patients on cardiac doses of aspirin may be enrolled in the study
• •12. Patients with pelvic floor dysfunction/defecatory disorder, based on patient history
• •13. Participation in another clinical study within one month prior to screening.
• •14. Women who are pregnant or lactating
• •15. Use of any medication for constipation relief during the study, except as rescue medication, as indicated by study rules
• •16. Inability to use an electronic daily Diary (on a computer, phone application, tablet or other electronic device) to report bowel movements, symptoms and medication usage
• •17. Any other condition which in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient's ability to complete the study